Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | GAK | O14976 | 2/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.41 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.41 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.41 |
| ▸ | HTR5A | P47898 | 4/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12875034 | 0.91 | SCN9A (0.43) | SCN9AGAKRIPK2COQ8ANLK | |
| SCHEMBL9909156 | 0.86 | SCN9A (0.49) | SCN9AGAKRIPK2COQ8ANLK | |
| SCHEMBL9909208 | 0.85 | SCN9A (0.51) | SCN9AGAKRIPK2COQ8ANLK | |
| SCHEMBL9909209 | 0.83 | HTR5A (0.49) | HTR5A | |
| SCHEMBL9909242 | 0.83 | HTR5A (0.59) | SCN9AHTR5APLAUPDE5A | |
| SCHEMBL9909205 | 0.82 | HTR5A (0.42) | HTR5A | |
| SCHEMBL16494659 | 0.82 | HTR5A (0.42) | SCN9AHTR5APLAUAVPR2AVPR1A | |
| SCHEMBL16509515 | 0.82 | HTR5A (0.48) | HTR5APLAU | |
| SCHEMBL9909247 | 0.80 | HTR5A (0.56) | SCN9AHTR5APLAU | |
| SCHEMBL9909294 | 0.78 | HTR5A (0.59) | HTR5APLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | SCN9A 412/4885GAK 1532/4885RIPK2 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.